152 related articles for article (PubMed ID: 15534052)
1. Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas.
Yamane T; Daimaru O; Ito S; Yoshiya K; Nagata T; Ito S; Uchida H
J Nucl Med; 2004 Nov; 45(11):1838-42. PubMed ID: 15534052
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.
Römer W; Hanauske AR; Ziegler S; Thödtmann R; Weber W; Fuchs C; Enne W; Herz M; Nerl C; Garbrecht M; Schwaiger M
Blood; 1998 Jun; 91(12):4464-71. PubMed ID: 9616140
[TBL] [Abstract][Full Text] [Related]
3. [FDG-PET on the day after first chemotherapy in malignant lymphoma].
Yamane T; Daimaru O; Itoh S; Nagata T; Yoshiya K; Itoh S; Uchida H; Shinai T; Imai T; Ohishi H
Nihon Igaku Hoshasen Gakkai Zasshi; 2002 Dec; 62(14):839-42. PubMed ID: 12607955
[TBL] [Abstract][Full Text] [Related]
4. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
[TBL] [Abstract][Full Text] [Related]
5. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
[TBL] [Abstract][Full Text] [Related]
6. Changes in 18F-FDG uptake within minutes after chemotherapy in a rabbit VX2 tumor model.
Song SL; Liu JJ; Huang G; Wang ZH; Song YY; Sun XG; Chen T
J Nucl Med; 2008 Feb; 49(2):303-9. PubMed ID: 18199614
[TBL] [Abstract][Full Text] [Related]
7. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
8. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
[TBL] [Abstract][Full Text] [Related]
9. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma.
Papajík T; Mysliveček M; Sedová Z; Buriánková E; Procházka V; Koranda P; Raida L; Kubová Z; Palová M; Kučerová L; Flodr P; Jarkovský J; Dušek L; Indrák K
Eur J Haematol; 2011 Jan; 86(1):32-7. PubMed ID: 20874822
[TBL] [Abstract][Full Text] [Related]
10. Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods.
Krak NC; van der Hoeven JJ; Hoekstra OS; Twisk JW; van der Wall E; Lammertsma AA
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):674-81. PubMed ID: 12640556
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
12. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
Doot RK; Dunnwald LK; Schubert EK; Muzi M; Peterson LM; Kinahan PE; Kurland BF; Mankoff DA
J Nucl Med; 2007 Jun; 48(6):920-5. PubMed ID: 17504870
[TBL] [Abstract][Full Text] [Related]
13. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Dittmann H; Langen HJ; Bares R
Lung Cancer; 2007 Feb; 55(2):165-71. PubMed ID: 17129635
[TBL] [Abstract][Full Text] [Related]
14. Added value of baseline 18F-FDG uptake in serial 18F-FDG PET for evaluation of response of solid extracerebral tumors to systemic cytotoxic neoadjuvant treatment: a meta-analysis.
Quarles van Ufford HM; van Tinteren H; Stroobants SG; Riphagen II; Hoekstra OS
J Nucl Med; 2010 Oct; 51(10):1507-16. PubMed ID: 20847179
[TBL] [Abstract][Full Text] [Related]
15. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT.
Nahmias C; Hanna WT; Wahl LM; Long MJ; Hubner KF; Townsend DW
J Nucl Med; 2007 May; 48(5):744-51. PubMed ID: 17475962
[TBL] [Abstract][Full Text] [Related]
16. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT.
Inglese E; Leva L; Matheoud R; Sacchetti G; Secco C; Gandolfo P; Brambilla M; Sambuceti G
J Nucl Med; 2007 Oct; 48(10):1662-9. PubMed ID: 17873124
[TBL] [Abstract][Full Text] [Related]
17. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
Buck AK; Halter G; Schirrmeister H; Kotzerke J; Wurziger I; Glatting G; Mattfeldt T; Neumaier B; Reske SN; Hetzel M
J Nucl Med; 2003 Sep; 44(9):1426-31. PubMed ID: 12960187
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
[TBL] [Abstract][Full Text] [Related]
19. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]